Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by remboon Mar 26, 2011 12:11pm

538 Views

Post# 18344936

8,152.500 shares at a .02 cent premium

I think it's a very positive sign that they were able to complete this at those terms.

LONDON, ONTARIO, Mar 25, 2011 (MARKETWIRE via COMTEX News Network) --

Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation") is pleased to announce that today it completed the first tranche of a non-brokered private placement and issued 8,152,500 units (the "Units") at a price of
.16 per Unit for gross proceeds of $1,304,400. The second tranche of the private placement is expected to close by the end of March 2011.

Each Unit consists of one common share and one warrant of the Corporation. Each warrant is exercisable into one common share of the Corporation at an exercise price of
.30 per share for a period of 18 months from the date of issue.

Bullboard Posts

Visionstate set to leverage success in the U.S. market